Getting an ADHD diagnosis can take years. For many patients - especially those who navigated long NHS waiting lists or used the Right to Choose pathway - finally reaching the prescribing stage feels like crossing a finish line.
For a significant number of people, there is another obstacle waiting on the other side.
The ADHD medication shortage in the UK has been disrupting prescriptions since at least autumn 2023, with recurring gaps in supply of some of the most commonly prescribed stimulant drugs. This guide explains what is happening, which medications have been affected, and what your practical options are.
Why do ADHD medication shortages happen?
Shortages of ADHD medication are not specific to the UK, but the problem has been particularly acute here.
The main reasons are structural. Most stimulant medications used to treat ADHD - including methylphenidate and lisdexamfetamine - are classified as Schedule 2 controlled drugs under the Misuse of Drugs Regulations 2001. This means manufacturers, importers and suppliers must hold Home Office controlled-drug licences, and the UK is required to submit annual production and use statistics to the International Narcotics Control Board under the UN drug conventions. These requirements limit how quickly supply can be scaled up when demand rises.
Demand has increased sharply. The number of ADHD diagnoses in England has grown significantly over the past decade, driven in part by better awareness, improved access pathways, and the expansion of Right to Choose. NHS England Digital's ADHD Management Information (November 2025) estimates around 2.5 million people in England have a recorded ADHD diagnosis - a figure that has risen steeply over the past ten years. Supply chains have not kept pace.
Manufacturer and distribution issues have compounded this. Shortages are often triggered by a single supplier pausing or reducing production, which - because the market for controlled stimulants is concentrated among a small number of manufacturers - has an outsized effect on overall availability. Elvanse, for example, is produced exclusively by Takeda; Concerta XL by Janssen.
Which ADHD medications have been affected by shortages?
The drugs most commonly reported as affected include:
Lisdexamfetamine (brand name: Elvanse)
Elvanse was one of the most severely affected ADHD medications during the initial shortage period from autumn 2023. Both the adult and children's formulations were disrupted. The position has improved: Takeda confirmed in May 2024 that most of its ADHD medicines were back in stock, and by November 2025 the Welsh Government's official ADHD medicines page described lisdexamfetamine disruptions as resolved. Note that Takeda has discontinued the separate Elvanse Adult formulation; it has been replaced by a single Elvanse capsule licensed for ages 6 and over.
Methylphenidate (brand names include: Ritalin, Concerta XL, Equasym, Medikinet)
Methylphenidate remains the most widely prescribed ADHD medication in the UK, though lisdexamfetamine is the fastest-growing and NICE now recommends both as joint first-line options for adults. As of late 2025 and into 2026, methylphenidate modified-release tablets are the product most consistently affected by ongoing supply disruption. Shortages have tended to affect specific brands and formulations rather than all methylphenidate products simultaneously - patients on Concerta XL, Xaggitin XL or Xenidate XL may find their specific version unavailable even when other methylphenidate products are in stock.
Mixed amphetamine salts (Adderall)
Adderall - the mixed amphetamine salt product widely used in the United States - is not licensed for routine use in the UK by the MHRA. Some patients have obtained it via private import arrangements; those patients have experienced disruption as a result of the global shortage.
Atomoxetine (brand name: Strattera)
Atomoxetine is a non-stimulant medication sometimes used when stimulants are not suitable or tolerated. It has also been subject to supply issues, though less consistently than stimulants.
The picture changes frequently. The NHS Specialist Pharmacy Service (SPS) publishes a live Medicines Supply Tool at sps.nhs.uk, which pharmacies and prescribers can use to check current shortage status and find prescribing guidance during disruptions. Separately, the NHSBSA publishes a list of active Serious Shortage Protocols (SSPs) - a distinct legal mechanism discussed below. Your pharmacist is usually the most up-to-date source for what is available locally.
What happens when your pharmacy cannot fill your prescription?
If your pharmacist cannot dispense your medication, they are required to tell you. They are not always required to proactively help you source an alternative - but most will try.
Your options at this point are:
- Ask the pharmacist to check other branches or nearby pharmacies. Many large chains have visibility across local stock. Independent pharmacies sometimes hold stock that chains do not.
- Contact your prescriber. If your exact medication or formulation is unavailable, your prescriber may be able to issue a new prescription for an equivalent drug or a different formulation - for example, switching from a modified-release to an immediate-release version of the same drug, or switching between brands of methylphenidate. This requires a new prescription; under the Misuse of Drugs Regulations 2001, a pharmacist cannot substitute a controlled drug without one.
- Ask about a serious shortage protocol. A serious shortage protocol (SSP) is a legal instrument that allows a pharmacist to dispense an alternative product without a new prescription. However, as of May 2026, no SSP has ever been issued for any ADHD medication. The Government confirmed in January 2025 that SSPs are not considered suitable for Schedule 2 controlled drugs such as methylphenidate except in very restricted circumstances, and there are no current plans to issue one. It is worth asking your pharmacist to confirm the current position, as this could change.
- Try a different pharmacy. Stock varies considerably between pharmacies, even within the same area. It is worth ringing around - larger supermarket pharmacies and hospital pharmacies sometimes hold stock that high-street branches do not.
A note on private prescriptions
Some patients who were diagnosed via a private provider or Right to Choose provider hold private prescriptions, or receive shared care under arrangements between their private prescriber and their GP.
Private prescriptions are subject to the same supply constraints. If your medication is unavailable, the shortage affects all prescriptions - NHS and private alike. However, if your shared care arrangement is not yet in place and your GP has not yet taken over prescribing, contact your diagnosing provider directly. They should be able to issue a new prescription or advise on alternatives within the terms of your care plan.
What if switching medication is suggested?
If your prescriber suggests switching medications because of a shortage, it is reasonable to ask:
- What is the equivalent dose?
- Is the new medication the same class of drug (stimulant or non-stimulant)?
- What should you expect in terms of how it works or how long it takes to take effect?
- Is the switch temporary or permanent?
Switching between medications - even within the same class - is not always straightforward, and your prescriber should monitor the transition. You should not be expected to manage a switch without clinical oversight.
Keeping records
Patients experiencing repeated disruption to their prescriptions are advised to keep a record of each time they cannot obtain their medication, including the date, the pharmacy, and what they were told. This documentation can be useful if you need to escalate a concern to your GP, your prescriber, or - in cases of significant clinical impact - to NHS England or the Parliamentary and Health Service Ombudsman.
The wider picture
Medication shortages are one part of a larger set of pressures facing ADHD patients in the UK. Many people who finally received a diagnosis - sometimes after waiting years - have since encountered significant changes to the Right to Choose pathway. From 1 April 2025, NHS England introduced Indicative Activity Plans that cap how many NHS-funded assessments individual providers can carry out each year. By November 2025, at least nine ICB areas in England had instructed providers to pause new Right to Choose assessment bookings, with some pauses expected to continue into 2026. A proposed NHS Payment Scheme clause that would have allowed ICBs to block referrals altogether was withdrawn in October 2025 following public pressure. Delayed shared care arrangements and GPs unwilling to take on prescribing remain widespread concerns. Shortages sit on top of these existing difficulties.
Advocacy organisations including ADHD UK and ADHD Action have both published resources for patients navigating access problems. ADHD UK in particular has been actively tracking shortage reports - its survey of over 1,000 patients found around 85% had been affected by supply disruption - and has challenged NHS decisions on Right to Choose through formal legal routes. If you are struggling to access medication, their resources and community spaces can be a useful source of real-time information on local availability.
By Find Care Compare Insights
Building the front door to healthcare